Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|April 6, 2026
Q1 2026 Recap: Top FDA Approvals
Author(s)HCPLive Editorial Staff
Fact checked by: Abigail Brooks, MA
A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.
Advertisement
Advertisement
The first quarter of 2026 brought a series of notable US Food and Drug Administration (FDA) approvals, highlighting continued momentum in innovation across diverse therapeutic areas, including rare diseases, endocrinology, dermatology, psychiatry, and hepatology. A recurring theme was the expansion of treatment options for underserved populations, particularly pediatric and rare disease communities, alongside a growing emphasis on more convenient, patient-centered care.
Related to this article
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Advertisement
Advertisement